Purpose: Comparing patient reported outcomes such as urinary and erectile function across institutions is critical for prostate cancer research and quality assurance. Such comparisons are complicated due to the use of different questionnaires. We aimed to develop a method to convert scores among 4 commonly used instruments. Materials and Methods: Patient reported data on urinary and sexual function were collected on 1,284 men with localized prostate cancer using the EPIC-26 (Expanded Prostate Index Composite), PCI (UCLA Prostate Cancer Index), SHIM (Sexual Health Inventory for Men) and I-PSS (International Prostate Symptom Scale) questionnaires. We investigated several methods to convert scores among questionnaires. Results: Conversion between EPIC and PCI urinary and sexual function subscales was best achieved using only the subset of questions asked on both questionnaires. For the conversion between EPIC or PCI erectile function scores and SHIM scores, we defined thresholds of poor, intermediate and good function as EPIC/PCI 0 to 40 and SHIM 1 to 7, EPIC/PCI 41 to 59 and SHIM 8 to 16, and EPIC/PCI 60 to 100 and SHIM 17 to 25, respectively. Urinary continence scores highly correlated for PCI and EPIC (r ¼ 0.94). No comparison was possible for I-PSS with EPIC and PCI due to differences in the domains addressed by these questionnaires. Conclusions: We have introduced methods to convert scores among the EPIC, PCI and SHIM questionnaires. While these conversion methods may introduce minor imprecision, to our knowledge they represent the best available tools to combine and compare patient reported outcomes that are assessed using different instruments in men undergoing radical prostatectomy or active surveillance.
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and provider level quality assessments. For a variety of reasons physician determination of patient urinary and sexual function is consistently inadequate and these outcomes must be evaluated by direct patient report using validated QOL questionnaires. 1 Various instruments exist to measure PROs in patients with prostate cancer, which can make comparisons for research and quality assurance difficult. For example, imagine a scenario in which 2 hospitals would like to implement a program comparing outcomes after radical prostatectomy so that surgeons can share knowledge and improve surgical technique and outcomes. One hospital measures postoperative sexual function using EPIC, 2 which is scored from 0 to 100 and includes questions on sexual desire and erectile function. The other hospital uses SHIM, which is scored from 1 to 25 and includes questions about erectile function only. If the average baseline adjusted score 1 year postoperatively is a SHIM score of 16 at one institution and an EPIC score of 52 at the other, there is no obvious way to know which hospital achieves better results.
Several previous publications have compared different prostate cancer outcome instruments in the attempt to derive a numerical conversion between raw scores (eg SHIM ¼ EPIC/4 þ 1).
3e6 A typical finding has been that because of variation in the included domains (for instance EPIC measures erectile function and sexual desire while SHIM measures only function), conversion between these 2 scales cannot be done. However, an alternative would be to use a subset of EPIC questions, compare those to SHIM and create a conversion factor that allows for comparison of the specific end point of erectile function.
We aimed to develop an appropriate and easily interpretable conversion method to facilitate comparisons among different prostate cancer PRO questionnaires without the constraint that all questions in an instrument must be included.
MATERIALS AND METHODS
The CaPSUREÔ registry is a prospective disease registry collecting data on men treated for prostate cancer at primarily community based clinical sites across the United States. Men are treated according to local urologist practices and are followed under central and/or local institutional review board supervision until death or study withdrawal. Participating clinicians report diagnostic, risk stratification and clinical outcomes data, and patients directly report quality of life before the first treatment and at least annually during followup using validated PRO questionnaires. Additional details have been published previously. 7 Until 2013 prostate cancer specific QOL was measured using PCI, 8 which includes domains for urinary continence, sexual function and bowel function as well as corresponding bother domains. In 2013 to better reflect the differential impact of nonsurgical treatments on QOL PCI was replaced with EPIC-26, which specifically includes urinary irritation and hormonal impact questions.
In anticipation of this switch we performed a 1-time cross-sectional sub study. Irrespective of primary treatment or followup duration since treatment, men were invited to answer an extended QOL survey including the full-length PCI, EPIC-26, SHIM and I-PSS. There is considerable but incomplete overlap between urinary questions in PCI and urinary continence questions in EPIC-26 and likewise between the sexual function questions in both instruments. Also, both are scaled 0 to 100 in each domain. As noted SHIM includes only questions on erectile function and it is scaled 1 to 25. Finally, I-PSS focuses on urinary obstructive and irritative symptoms, and is scored 1 to 35 with a single additional question about overall urinary QOL.
Therefore, a principal goal of this sub study was to determine the extent to which scores on each of these instruments are interchangeable. We also sought to find ways to convert urinary function scores among EPIC-26, PCI and I-PSS, and sexual function scores between EPIC-26, PCI and SHIM.
We investigated several potential methods to convert questionnaire scores (supplementary Appendix, http:// jurology.com/). We decided to convert between the EPIC and PCI scales using questions that were asked in both questionnaires and then finding the appropriate conversion factor between the scores. Modified urinary function scores on a scale of 0 to 100 were calculated for only questions common to the EPIC-26 and PCI questionnaires. Since there is no overlap in questions between EPIC-26 or PCI and I-PSS, we investigated whether questions on overall urinary bother from EPIC-26 and PCI could be compared to the I-PSS question regarding quality of life with urinary symptoms.
We converted sexual function scores in the EPIC-26 and PCI questionnaires in the same way that we had converted urinary function scores using questions that were common to both questionnaires. Since PCI but not EPIC-26 asks about libido, only questions on erectile function were included in the modified sexual function score.
Scores from the SHIM questionnaire are often categorized. 9 Given the different range of SHIM and PCI/EPIC scores, we predicted that it would be preferable to ensure consistent categorization between scales than attempt a direct numerical conversion. Thus, we determined cut points for EPIC-26 and PCI scores that would enable consistent categorization of sexual function.
The supplementary Appendix (http://jurology.com/) shows additional details on methodology. All analyses were performed with StataÒ, version 13.
RESULTS
The cohort consisted of 1,284 men who completed all 4 questionnaires after prostate cancer treatment or while on active surveillance. Table 1 summarizes patient characteristics. Patients who completed the surveys were younger and more likely to undergo radical prostatectomy compared to those who did not complete the surveys or did not respond (p <0.01).
A modified urinary score was calculated using the 4 questions asked on the EPIC-26 and PCI questionnaires. The modified urinary function score on a scale of 0 to 100 was calculated as the mean score of all questions answered by men who answered at least 3 of the 4 included questions (Appendix 1). Median and quartiles of the modified EPIC-26 urinary score in 1,284 respondents and the PCI score in 1,249 were identical at 85.5 (IQR 73e100) and there was high correlation between the 2 scores (concordance correlation coefficient r ¼ 0.94, fig. 1 ).
Due to the overlapping distribution of the urinary continence scores and the similarity in questions between EPIC-26 and PCI, we believe that the best way to convert between EPIC-26 and PCI scores would be a 1:1 conversion of the urinary continence score calculated using only the questions common to the questionnaires. We stress that this conversion should be restricted to patients treated with radical prostatectomy and active surveillance since questions on irritative urinary symptoms commonly caused by radiation are not included in the PCI questionnaire. Therefore, they were not included in the modified urinary continence scores.
Conversely, questions about urinary function or symptoms were not comparable between I-PSS and EPIC-26 or PCI. The PCI questionnaire focuses exclusively on urinary continence and bother, and EPIC focuses on urinary continence and irritation while I-PSS asks about a variety of general urinary symptoms, focusing primarily on obstruction. We considered including obstructive or irritative symptoms only since these domains are addressed on EPIC-26 and I-PSS. However, correlations between these questions were weak for incomplete emptying (0.61), weak stream (0.70) and frequency (0.60). We then explored the 1 question about general urinary bother on each questionnaire but found no cut points that identified bothersome urinary symptoms with good concordance among questionnaires (supplementary Appendix, http://jurology. com/). Based on these analyses we concluded that it would be inappropriate to convert scores between I-PSS and EPIC-26 or PCI.
We next explored ways to convert sexual function scores between the EPIC-26, PCI and SHIM questionnaires. As with urinary function, several sexual function questions were identical on EPIC-26 and PCI. Five questions that occurred on both questionnaires and addressed erectile function were included in the modified sexual function subscale (Appendix 1). Questions on libido or sexual desire were excluded from this score. The modified sexual function score was calculated on a scale of 0 to 100 as the mean score of all nonmissing answers of patients who answered at least 3 of the 5 included questions. The median modified sexual function score on EPIC-26 was 20 (IQR 5e55). On the PCI questionnaire the median score was 20 (IQR 6.6e55). As seen with urinary function scores, the distribution of sexual function scores in EPIC-26 and PCI overlapped and all questions included in this score were asked on both questionnaires. Again the correlation was excellent (concordance correlation coefficient r ¼ 0.96, fig. 2 ). As such we believe that the best way to convert between EPIC-26 and PCI scores on sexual function was to do a 1:1 conversion of the scores including only the 5 questions common to both questionnaires.
To convert between SHIM and EPIC-26 or PCI scores we searched for score cut points that would enable us to classify patients as having good, intermediate or poor sexual function, corresponding to the categorization of SHIM scores (figs. 3 and 4). A threshold of 40 for poor function on the EPIC-26 and PCI questionnaires concordantly classified 86% of all patients based on the modified EPIC-26 score (table 2). The supplementary Appendix (http:// jurology.com/) shows further details. A cut point of 59 was chosen for good function on both questionnaires, which led to concordant classifications on EPIC-26 for 92% of all patients. Concordance rates of PCI scores were similar to EPIC concordance rates (table 2) . While these cut points accurately classified patients who reported good or poor function on the SHIM questionnaire, they were less accurate for classifying patients who reported SHIM scores in the intermediate function range. However, those patients represented only 10% of the cohort.
Psychometric properties of the modified EPIC and PCI urinary continence and sexual scores were good. The supplementary Appendix (http://jurology. com/) shows details. Appendix 2 shows details on how to calculate the scores.
DISCUSSION
The ability to document and compare outcomes, including PROs, is vital to ongoing research and to a wide range of quality improvement efforts in medicine. Multiple questionnaires are used to measure PROs after prostate cancer treatment. These questionnaires were developed with different goals and methodologies, and they ask different questions and are scored in different ways. Such differences complicate comparisons of prostate cancer PROs among or within institutions using different questionnaires.
Given the brevity and ease of calculation of I-PSS and SHIM, they are widely used in clinical practice. PCI was the first comprehensive QOL instrument specifically validated for patients with prostate cancer, although its questions tend to focus on the adverse effects of prostatectomy rather than of radiation or other treatments. EPIC was developed from PCI to capture these differential effects more completely. The shortened EPIC-26, which is perhaps most frequently used in contemporary research, was endorsed for outcomes assessment by ICHOM (International Consortium for Health Outcomes Measurement) with 2 important modifications, including the addition of a question specifically assessing libido and a question on the use of phosphodiesterase inhibitors or other erectile aids. 1 The latter is a particularly important addition since the question is not asked on many standard PRO questionnaires except the Memorial Sloan Kettering Cancer Center questionnaire. 10 This leaves patients who use such aids confused as to whether to answer by assuming use or nonuse.
The lack of standardized methods to collect and compare prostate cancer PROs has been known for some time. An attempt by AUA (American Urological Association) to synthesize multiple QOL instruments in 2007 was unsuccessful due to differences among the instruments. 5 Several studies have been published that investigated comparisons or conversions between QOL questionnaires. Of 2 studies that attempted to compare sexual function scores between instruments one was unable to find an appropriate conversion 11 while the other was only able to identify a threshold value to define men as potent or impotent. 12 While Namiki et al reported conversions between total EPIC and PCI urinary and sexual function scores, 4 we believe that they are inappropriate, given that the EPIC and PCI questionnaires address different domains of sexual and urinary function. Hedgepeth et al aimed to compare scores from multiple instruments by breaking down some instruments into subscales and including individual questions from other instruments in the analysis. 6 However, they did not attempt to convert scores between instruments or provide a method to standardize score comparisons.
Our approach differs from these generally unsuccessful attempts to convert between different prostate cancer PROs using total questionnaire scores, including those of the AUA effort. 5 Instead of treating existing PRO questionnaires as inviolable with the only option being the comparison of total domain scores, we investigated the use of subsets of questions addressing comparable domains. We have developed a methodology to convert between urinary and sexual function scores on the EPIC-26, PCI and SHIM questionnaires. We believe that the key to an appropriate conversion between quality of life instruments is converting only between symptom domains that are addressed in both instruments.
While these conversion methods provide an appropriate comparison between instruments, we acknowledge certain limitations. The majority of patients in our sample underwent radical prostatectomy. While we assessed conversions for radical prostatectomy and radiation cases separately (supplementary Appendix, http://jurology. com/), this conversion may be less accurate when applying it in patients treated with methods other than surgery, given the explicit focus of PCI questions on continence rather than on other urinary symptoms. We plan to perform further research to examine our approach for patients treated nonsurgically. An additional limitation is that the combined survey was administered as a 1-time cross-sectional sub study so that we could not specifically analyze the relative stability of any instrument with time.
Our proposed conversion introduces a degree of imprecision as the conversion algorithms that we propose do not lead to 100% concordance between instruments. However, we believe that this is minor compared to the other sources of imprecision associated with quality assurance efforts, such as incomplete adjustment for case mix, postoperative care or statistical variation. For instance, the 95% CI is AE 10% around a functional recovery rate of 50% for a surgeon with 100 prostatectomy cases.
CONCLUSIONS
Our proposed conversions provide appropriate and straightforward ways to compare surgeons and institutions that measure outcomes using different PRO instruments. This method would enable historical data collected on PCI to be combined with more contemporary data using EPIC-26 and allow for sexual function scores collected on SHIM to be compared to scores from EPIC-26 and PCI. Although we intend to perform further research in this area, we believe that our approach can be used for other research projects and be implemented into current and emerging quality assurance programs. 
APPENDIX 2 Algorithms for Conversion
To compare between EPIC-26 and PCI version 1 questionnaires for urinary incontinence: Convert answers to questions to scores on 0-100 scale as per scoring manuals for each questionnaire EPIC-26: sum scores from questions 2, 3, 4a and 5 for patients who have answered at least 3 out of the 4 questions, and divide by the total number of questions answered PCI version 1: sum scores from questions 13, 14, 15a and 16 for patients who have answered at least 3 out of the 4 questions, and divide by the total number of questions answered This gives a urinary function score on a scale of 0-100 for both EPIC-26 and PCI version 1, and these scores can be converted 1:1 between the 2 questionnaires The urinary function scores calculated for EPIC-26 and PCI version 1 should be applied only to patients who were treated with surgery or active surveillance, since none of the included questions ask about urinary symptoms related to radiation, such as frequency, urgency or pain To compare between EPIC-26, PCI version 1 and SHIM questionnaires for sexual function:
SHIM questionnaire is about erectile function, while the EPIC-26 and PCI version 1 questionnaires are about sexual function more generally.
We excluded questions about libido and general sexual function from the sexual function scores (question 8b from the EPIC-26, and questions 22a and 22c from the PCI version 1) so that these scores measured erectile function only and could be more easily compared to the SHIM scores EPIC-26: sum scores from questions 8a, 9, 10, 11 and 12 for patients who have answered at least 3 out of the 5 questions, and divide by the total number of questions answered PCI version 1: sum scores from questions 22b, 23, 24, 27 and 28 for patients who have answered at least 3 out of the 5 questions, and divide by the total number of questions answered This gives a sexual function (specifically erectile function) score on a scale of 0-100 for both EPIC-26 and PCI version 1, which can be converted 1:1 between the 2 questionnaires SHIM scores were calculated by summing the number of points from all 5 questions SHIM scores of 1-7 were considered poor function, 8-16 was considered intermediate function, and 17-25 were considered good function To convert between EPIC-26 or PCI version 1 and SHIM, EPIC-26 and PCI version 1 scores were categorized into poor, intermediate and good function Since EPIC-26 and PCI version 1 sexual function scores can be converted 1:1 between the 2 questionnaires, the cut points for categorizing these scores were the same for both questionnaires Scores on the EPIC-26 or PCI version 1 of 40 or less were considered poor function, scores greater than 40 but less than 59 were considered intermediate function, and scores of 59 or higher were considered good function
